Skip to content

NIV - NAVA vs NIV - PS for COPD Exacerbation

Non-invasive Ventilation (NIV) - Neurally Adjusted Ventilatory Assist (NAVA) vs NIV for Acute Hypercapneic Respiratory Failure in COPD: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02912689
Acronym
NAVA-NICE
Enrollment
40
Registered
2016-09-23
Start date
2016-09-30
Completion date
2017-12-31
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation

Keywords

COPD, Non-invasive ventilation, NAVA

Brief summary

Number of Patients: Total no. of patients = 40 patients NIV-PSV group (Group A) = 20 NIV-NAVA group (Group B) = 20 Inclusion criteria a) Patients of Chronic obstructive pulmonary disease with acute hypercapnic respiratory failure (pH \< 7.35 and PaCO2 \>45 mmHg) requiring noninvasive ventilation and with no indication for invasive mechanical ventilation. Exclusion criteria 1. Patient with any contra-indication for insertion of nasogastric tube (like recent gastrointestinal bleeding in previous 30 days, esophageal varices) 2. Patient with any contraindication of noninvasive ventilation (such as hemodynamic instability, active gastrointestinal bleed etc) 3. Patients with a known neuromuscular, central or peripheral nervous system disorder. 4. Patient not willing to give consent. Control(s): Patients receiving pressure support ventilation (NIV-PSV) will act as control Study design: Randomized interventional study Dosages of drug: None Duration of treatment: Till patient improves or requires invasive ventilation. Brief Methodology Patients of COPD with acute exacerbation will be randomized into two groups (group A and group B) to receive NIV-PSV or NIV-NAVA respectively. A special naso-gastric catheter (EAdi-catheter) will be placed in all patients. In each mode, NIV will be applied using a non-vented oro-nasal mask that will be fitted enough to avoid air leaks. Patients in Group A will receive NIV-PS and Group B will receive ventilation via NIV-NAVA. Pressure support and PEEP levels will be set by the treating physician to achieve a tidal volume (Vt) of 6 to 8 mL/kg of ideal body weight. NAVA level will be adjusted to match peak pressures of NIV-PSV using manufacturer-supplied software. After stabilization, a 30-min period of each NIV trial will be recorded and manually analyzed offline. Subsequent readings will be taken at 2, 6 and at 24 hours and then at 6 hourly interval from day 2 onwards. In each trial, patient-ventilator asynchronies (ineffective efforts, auto triggering, premature cycling, delayed cycling, and double triggering) will be determined on EAdi, airway pressure, and flow signal. The number of each type of asynchrony, defined as the number of events per minute, will be determined for each recording period. The asynchrony index (AI), in percentage, will be calculated as described previously, and an AI \>10% will be considered severe asynchrony. Patient comfort level after each mode of ventilation will be assessed by using visual analogue scale. Various clinical, ventilatory and arterial blood gas parameters will be recorded. Statistical analysis Data will be expressed as mean ± standard deviation (SD), or percentage. Differences in continuous variables between the two groups will be compared using student's t test (or Mann-Whitney U test); while differences in categorical data will be compared using the chi- square test (or Fisher's exact test). A p value of less than 0.05 will be considered statistically significant.

Interventions

DEVICENeurally Adjusted Ventilator Assist

NAVA during Non-invasive ventilation

DEVICEPressure support ventilation

PS during Non-invasive ventilation

Sponsors

All India Institute of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients of Chronic obstructive pulmonary disease with acute hypercapnic respiratory failure requiring noninvasive ventilation and with no indication for invasive mechanical ventilation will be included in the study.

Exclusion criteria

* Patient with any contraindication for insertion of nasogastric tube (like recent gastrointestinal bleeding in previous 30 days, Esophageal varices) * Patient with any established contraindication of noninvasive ventilation. (Like Hemodynamic instability, active GI bleed etc) * Patients with a known neuromuscular, Central or peripheral nervous system disorder. * Patient not willing to give consent.

Design outcomes

Primary

MeasureTime frameDescription
Difference in the number of patient ventilator asynchronyEntire period of ventilatory support, an average of 5 daysTo assess the difference of number of patient ventilator asynchrony

Secondary

MeasureTime frameDescription
Difference in rate of NIV failureEntire hospital stay, an average of 7 daysTo assess the difference of rate of NIV failure
Difference in total duration of ventilatory supportEntire hospital stay, an average of 7 daysTo assess the difference in total duration of ventilatory support

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026